Getting your player ready...
An experimental drug developed by Seattle Genetics Inc. and Takeda Pharmaceutical Co. wiped out tumors in one-third of patients with hard-to-treat Hodgkin’s lymphoma and reduced the cancer by half in another 40 percent, a study has found.
Overall, 94 percent of 102 patients had their tumors shrink by at least a quarter, an “unheard-of” level of improvement in people who had failed other treatments, said study leader Robert Chen, an assistant professor at City of Hope, a nonprofit cancer center in Duarte, Calif. He presented the results Monday at the American Society of Hematology meeting in Orlando, Fla.
The drug, SGN-35, might be approved by federal regulators late next year.
Bloomberg News
